NASDAQ:ARVN Arvinas (ARVN) Stock Price, News & Analysis $9.12 +0.03 (+0.27%) Closing price 03:59 PM EasternExtended Trading$9.09 -0.04 (-0.44%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Arvinas Stock (NASDAQ:ARVN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Arvinas alerts:Sign Up Key Stats Today's Range$8.96▼$9.3450-Day Range$8.55▼$13.4852-Week Range$6.05▼$14.51Volume580,536 shsAverage Volume862,021 shsMarket Capitalization$588.75 millionP/E RatioN/ADividend YieldN/APrice Target$14.69Consensus RatingHold Company Overview Arvinas, Inc. (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems. The company’s most advanced clinical candidates address hormone-driven cancers. ARV-110 (bavdegalutamide) is being evaluated for the treatment of metastatic castration-resistant prostate cancer, while ARV-471 (voredabolu) is in development for ER+/HER2- breast cancer. Both programs have shown favorable pharmacokinetic profiles in early-phase trials and reflect Arvinas’s strategy of advancing a focused pipeline of next-generation small molecules designed to degrade pathogenic proteins. Since its founding in 2013 and incorporation in New Haven, Connecticut, Arvinas has established collaborative partnerships with leading pharmaceutical companies to expand the reach of its PROTAC platform. Agreements with Pfizer and Roche, among others, provide access to complementary expertise in oncology and other therapeutic areas. The company conducts research and development in the United States and maintains relationships with regulatory authorities in North America and Europe as it pursues global clinical development. Arvinas is led by President and Chief Executive Officer Robert A. Ross, who joined the company in 2022 following a tenure at a major pharmaceutical association. Under his leadership, the company continues to advance its pipeline while building a broader platform for targeted protein degradation. Arvinas remains committed to translating its scientific innovations into transformative therapies for patients with unmet medical needs. AI Generated. May Contain Errors. Read More Arvinas Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreARVN MarketRank™: Arvinas scored higher than 50% of companies evaluated by MarketBeat, and ranked 511th out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingArvinas has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on no strong buy ratings, 8 buy ratings, 3 hold ratings, and 3 sell ratings.Upside PotentialArvinas has a consensus price target of $14.69, representing about 61.0% upside from its current price of $9.13.Amount of Analyst CoverageArvinas has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Arvinas' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Arvinas are expected to decrease in the coming year, from ($2.85) to ($3.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arvinas is -2.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arvinas is -2.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArvinas has a P/B Ratio of 1.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Arvinas' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.39% of the float of Arvinas has been sold short.Short Interest Ratio / Days to CoverArvinas has a short interest ratio ("days to cover") of 7.27.Change versus previous monthShort interest in Arvinas has recently increased by 0.66%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArvinas does not currently pay a dividend.Dividend GrowthArvinas does not have a long track record of dividend growth. News and Social Media1.5 / 5News Sentiment-0.54 News SentimentArvinas has a news sentiment score of -0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Arvinas this week, compared to 6 articles on an average week.Search Interest10 people have searched for ARVN on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days. Company Ownership2.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Arvinas insiders have sold 252.83% more of their company's stock than they have bought. Specifically, they have bought $268,000.00 in company stock and sold $945,574.00 in company stock.Percentage Held by Insiders7.30% of the stock of Arvinas is held by insiders.Percentage Held by Institutions95.19% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arvinas' insider trading history. Receive ARVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARVN Stock News HeadlinesArvinas Employees Give Back During Company-wide Impact DayMay 18, 2026 | globenewswire.comBullish: Analysts Just Made A Noticeable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) ForecastsMay 16, 2026 | finance.yahoo.comA 17-year investing experiment investigated in DublinPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.May 22 at 1:00 AM | Porter & Company (Ad)Earnings Beat: Arvinas, Inc. (NASDAQ:ARVN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsMay 15, 2026 | uk.finance.yahoo.comInsider Selling: Arvinas (NASDAQ:ARVN) CAO Sells 1,919 Shares of StockMay 14, 2026 | insidertrades.comArvinas (NASDAQ:ARVN) Price Target Raised to $18.00 at BTIG ResearchMay 14, 2026 | americanbankingnews.comArvinas Q1 2026 earnings previewMay 12, 2026 | msn.comWhat To Expect From Arvinas Inc (ARVN) Q1 2026 EarningsMay 12, 2026 | finance.yahoo.comSee More Headlines ARVN Stock Analysis - Frequently Asked Questions How have ARVN shares performed this year? Arvinas' stock was trading at $11.86 at the beginning of 2026. Since then, ARVN shares have decreased by 23.1% and is now trading at $9.1250. How were Arvinas' earnings last quarter? Arvinas, Inc. (NASDAQ:ARVN) announced its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.90) earnings per share for the quarter, beating the consensus estimate of ($0.95) by $0.05. The business's quarterly revenue was down 91.7% on a year-over-year basis. Read the conference call transcript. Is Arvinas buying back stock? Arvinas' Board of Directors approved a stock buyback program on Wednesday, September 17th 2025, which authorizes the company to repurchase $100,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 17.9% of its shares through open market purchases. Shares buyback programs are typically a sign that the company's board believes its shares are undervalued. When did Arvinas IPO? Arvinas (ARVN) raised $112 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 7,500,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO. Who are Arvinas' major shareholders? Arvinas' top institutional investors include Dimensional Fund Advisors LP (0.75%), Brummer Multi Strategy AB (0.44%), Wasatch Advisors LP (0.44%) and Caxton Associates LLP (0.40%). Insiders that own company stock include John G Houston, Randy Teel, Andrew Saik, Noah Berkowitz, Sean A Cassidy, Ian Taylor, Briggs Morrison, Ronald Peck and David K Loomis. View institutional ownership trends. How do I buy shares of Arvinas? Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arvinas own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arvinas investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET). Company Calendar Last Earnings5/12/2026Today5/22/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 8 days, ARVN's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARVN CIK1655759 Webwww.arvinas.com Phone(203) 535-1456FaxN/AEmployees420Year FoundedN/APrice Target and Rating Average Price Target for Arvinas$14.69 High Price Target$24.00 Low Price Target$6.00 Potential Upside/Downside+61.0%Consensus RatingHold Rating Score (0-4)2.36 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($3.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$80.80 million Net Margins-247.54% Pretax Margin-247.32% Return on Equity-44.38% Return on Assets-28.38% Debt Debt-to-Equity RatioN/A Current Ratio5.44 Quick Ratio5.44 Sales & Book Value Annual Sales$262.60 million Price / Sales2.24 Cash FlowN/A Price / Cash FlowN/A Book Value$5.99 per share Price / Book1.52Miscellaneous Outstanding Shares64,520,000Free Float59,811,000Market Cap$588.75 million OptionableOptionable Beta1.79 Social Links The 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:ARVN) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredTo Avoid 67 Million Blackouts, Trump Signs Emergency Backing of New Energy TechPresident Trump has used emergency executive powers to back a new energy technology described as 326 times mor...Altimetry | SponsoredElon’s Biggest Launch Ever: 15x Bigger Than SpaceXThe Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert Luke Lango was ranked Amer...InvestorPlace | SponsoredHidden on Tesla's filing: A $12 billion "super startup"Tesla's most recent SEC filing contains a single line showing $12 billion in revenue from a new venture Elon M...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arvinas With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
